Background: to evaluate whether prior SARS-CoV-2 infection affects side effects and specific antibody production after vaccination with BNT162b2. Methods: We included 1106 health care workers vaccinated with BNT162b2. We assessed whether prior SARS-CoV-2 infection affects the number and type of side effects and performed a nested case-control analysis comparing plasma levels of specific IgG titers between SARS-CoV-2-naive and previously infected subjects after the first and the second vaccine doses. Results: After the first dose, SARS-CoV-2-naive subjects experienced side effects more often than SARS-CoV-2 naive subjects. Individuals with prior SARS-CoV-2 infection more often reported pain at the injection site, weakness, and fever than SARS-CoV-2-naive subjects. After the second dose, the frequency of side effects was similar in the two groups. All subjects with prior SARS-CoV-2 infection developed either a high (>100 AU/mL) or intermediate (10-100 AU/mL) antibody titer. Among SARS-CoV-2-naive subjects, the majority developed an intermediate titer. After the second dose, a high (>2000 AU/mL) antibody titer was more common among subjects with prior SARS-CoV-2 infection. Conclusions: vaccine-related side effects and a higher anti-SARS-CoV-2-RBD IgG titer were more common in subjects with previous infection than in SARS-CoV-2-naive after the first, but not after the second dose of the BNT162b2 vaccine.

Ferrari, L., Compagno, M., Campogiani, L., Teti, E., Mulas, T., Checchi, D., et al. (2022). Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine. VACCINES, 10(8), 1238 [10.3390/vaccines10081238].

Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine

Elisabetta Teti;Laura Ceccarelli;Sandro Grelli;Massimo Andreoni;loredana sarmati
;
Marco Iannetta
2022

Abstract

Background: to evaluate whether prior SARS-CoV-2 infection affects side effects and specific antibody production after vaccination with BNT162b2. Methods: We included 1106 health care workers vaccinated with BNT162b2. We assessed whether prior SARS-CoV-2 infection affects the number and type of side effects and performed a nested case-control analysis comparing plasma levels of specific IgG titers between SARS-CoV-2-naive and previously infected subjects after the first and the second vaccine doses. Results: After the first dose, SARS-CoV-2-naive subjects experienced side effects more often than SARS-CoV-2 naive subjects. Individuals with prior SARS-CoV-2 infection more often reported pain at the injection site, weakness, and fever than SARS-CoV-2-naive subjects. After the second dose, the frequency of side effects was similar in the two groups. All subjects with prior SARS-CoV-2 infection developed either a high (>100 AU/mL) or intermediate (10-100 AU/mL) antibody titer. Among SARS-CoV-2-naive subjects, the majority developed an intermediate titer. After the second dose, a high (>2000 AU/mL) antibody titer was more common among subjects with prior SARS-CoV-2 infection. Conclusions: vaccine-related side effects and a higher anti-SARS-CoV-2-RBD IgG titer were more common in subjects with previous infection than in SARS-CoV-2-naive after the first, but not after the second dose of the BNT162b2 vaccine.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/17
English
BNT162b2
COVID-19
SARS-CoV-2
antibody titer
healthcare workers
side effects
vaccines
Ferrari, L., Compagno, M., Campogiani, L., Teti, E., Mulas, T., Checchi, D., et al. (2022). Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine. VACCINES, 10(8), 1238 [10.3390/vaccines10081238].
Ferrari, L; Compagno, M; Campogiani, L; Teti, E; Mulas, T; Checchi, D; Alessio, G; Caldara, F; Coppola, L; De Simone, G; Ceccarelli, L; Spalliera, I; Vitale, P; Grelli, S; Andreoni, M; Sarmati, L; Iannetta, M
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
vaccines-10-01238.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 1.2 MB
Formato Adobe PDF
1.2 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/305415
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact